CytoMed Therapeutics LtdNASDAQ:GDTC
- LAST PRICE2.2595
- TODAY'S CHANGE (%)0.0595 (2.7045%)
- Bid / Lots0.8760/ 2
- Ask / Lots2.3500/ 5
- Open / Previous Close2.0500 / 2.2000
- Day Range
- 52 Week Range
- Volume2,686
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GDTC |
|---|---|---|
| 09:44 ET | 200 | 2.05 |
| 09:46 ET | 150 | 2.05 |
| 10:00 ET | 200 | 2.1087 |
| 10:08 ET | 100 | 2.1 |
| 11:23 ET | 100 | 2.35 |
| 01:02 ET | 400 | 2.1 |
| 01:09 ET | 100 | 2.2506 |
| 02:25 ET | 120 | 2.15 |
| 02:59 ET | 500 | 2.18 |
| 03:57 ET | 200 | 2.2595 |
Nov 20, 2024
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies, from 7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CytoMed Therapeutics Ltd | 26.1M | -11.5x | --- |
Mira Pharmaceuticals Inc | 19.5M | -1.8x | --- |
Eom Pharmaceutical Holdings Inc | 19.3M | -3.9x | --- |
UNITY Biotechnology Inc | 19.2M | -1.0x | --- |
Goldenwell Biotech Inc | 19.8M | -139.9x | --- |
Enlivex Therapeutics Ltd | 19.9M | -0.8x | --- |
Company Information
CytoMed Therapeutics Limited is a biopharmaceutical company. It is focused on harnessing its licensed proprietary technologies to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The CTM-GDT product candidate consists of expanded allogeneic gamma delta T cells. It also focuses on Off-the-shelf Donor-derived Gamma Delta T Cells Technology.
Contact Information
- Headquarters
- #08-22 One Commonwealth 1 Commonwealth Lane, Singapore 149544
- Phone
- ---
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $26.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 11.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.20 |
Book Value | $0.72 |
P/E Ratio | -11.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
